VCEL
- Vericel Corporation
()
Overview
Company Summary
Vericel Corporation (VCEL) is a biopharmaceutical company that specializes in the development and commercialization of advanced cell therapies for the treatment of patients with severe diseases and conditions. The company focuses on developing therapies that leverage the patient's own cells to repair, regenerate, or restore normal function to damaged tissues.
Vericel is known for its two FDA-approved cell therapy products: MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is used for the treatment of articular cartilage defects in the knee, while Epicel is used to treat patients with severe burn injuries.
These cell therapies involve the collection of a small sample of the patient's cells, which are then cultured and expanded in Vericel's specialized manufacturing facilities. The expanded cells are then implanted back into the patient, either directly onto damaged tissue or as a graft.
Vericel's scientific and technological expertise lies in the field of regenerative medicine, where it aims to harness the potential of cells to restore and repair tissues that have been damaged by disease or injury. The company's research initiatives also focus on exploring cell-based therapies for other areas like cardiac diseases, autoimmune disorders, and neurodegenerative conditions.
In addition to developing cell therapies, Vericel also provides comprehensive support to physicians and patients through training programs, educational resources, and patient assistance programs. The company's goal is to improve patient outcomes and quality of life by providing innovative and effective cell-based treatments.
Overall, Vericel Corporation is at the forefront of the cell therapy industry, dedicated to developing and commercializing advanced regenerative medicine products that have the potential to significantly impact patients' lives.